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Abstract

Characteristics of Alveolar Bone Marrow Cells from Patients Undergoing Dental Extractions or
Dental Implant Therapy
By: Meng Huan Lee D.M.D

A thesis submitted in partial fulfillment of the requirements for the degree of Master of Science
in Dentistry at Virginia Commonwealth University

Virginia Commonwealth University, March 2020

Thesis Advisor: Zhao Lin, B.D.S., M.S., M.M.Sc., Ph.D.
Associate Professor, Department of Periodontics

Abstract: Alveolar bone marrow stromal cells (aBMSCs) play important roles in craniofacial
wound healing. To establish an easy, efficient and reliable method to harvest aBMSCs, we
compared three different methods: extraction socket aspiration, osteotomy aspiration and bone
core digestion. Samples of aBMSC were collected from two groups of subjects. Group 1 (dental
extraction): after dental extraction, 22.5-gauge needles were used to collect 0.5-1cc marrow
aspirate. Group 2 (dental implant): during implant surgeries, bone core and 0.5-1cc marrow
aspirate were obtained from the osteotomy. Samples were cultured in petri dishes and attached
cells were expanded. The population doubling time (PDT), surface markers, and osteogenic
differentiation potential of these cells were studied. In total 12 subjects were enrolled in the

study. The success rates of generating aBMSCs from extraction socket aspiration, osteotomy
aspiration and bone core digestion were 42.8% (3/7), 40% (2/5) and 80% (4/5), respectively.
Cells from extraction socket aspiration had the fastest proliferation rate among the three sample
types, followed by bone core and osteotomy aspiration, as shown in PDTs and DNA fold
changes. After isolation and expansion, all the aBMSCs expressed high levels of CD 73, CD90,
and CD105, however, the expression of CD146 varied among the cells. Cells derived from bone
core had the highest ALP activity after osteogenic induction, followed by cells from osteotomy
aspiration, and then extraction aspiration. Taken together, bone core samples obtained during
implant surgery is a more reliable source for generating aBMSCs and aBMSCs harvested from
different methods may have different characteristics.

Key words: Stem cell, alveolar bone marrow stromal cells, regeneration, implant therapy.
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Introduction
Untreated periodontitis may lead to progressive loss of clinical attachment, followed by
destruction of the periodontal ligament and the supporting bone around the periodontium which
may ultimately lead to tooth loss1. Tooth loss is a severe public problem, especially in the elderly
population, that causes loss of chewing function, malnutrition, esthetic problems and decreased
life quality. It is estimated that over 240 million people in the industrialized world are missing
one or more teeth, and 40% of the Western population has lost at least one tooth2. Based on the
National Health and Nutrition Examination Survey (NHANES) in 2004, seniors over 65 years of
age lose an average of 10 teeth per person, and 27.7% of them have no remaining teeth2. Dental
implants have become a standard of care for the replacement of missing teeth and over 1 million
implants placed annually in the United States. Although the long term success rate of dental
implants is over 90%3–6, the clinical outcome of implant therapy is impacted by many systemic
conditions, such as diabetes7, smoking8 and osteoporosis9,10, and local factors that include
insufficient alveolar bone volume11.
Regenerative medicine strives to repair organs and/or tissues affected by chronic disease12.
Stems cells are applied in regenerative medicine and disease therapeutics, however, the function
and nature of mesenchymal stem cells (MSCs) have gone through a number of paradigm
shifts13,14. Currently, it is believed that MSCs contribute to tissue regeneration through two
important functions; first, the ability to differentiate into distinct end-stage cell types that include
bone, cartilage, muscle, tendons, ligaments, fat, dermis, and other connective tissues; second, the
ability to initiate a broad spectrum of bioactive molecules that promote tissue regeneration in
injured sites15. In regenerative medicine, embryonic stem cells (ESCs), tissue specific progenitor
1

stem cells (TSPSCs), mesenchymal stem cells (MSCs), umbilical cord stem cells (UCSCs), bone
marrow stem cells (BMSCs), and induced pluripotent stem cells (iPSCs) have been widely
studied 12. ESCs have been shown to treat spinal cord injuries16, promote macular defect
recovery and vision restoration17, regenerate liver tissue after injuries18, and restore damaged
cartilage in athletes19. TSPSCs have been used to regenerate cochlear20, ischemic myocardium21,
and goblet mucosa in intestine22. UCSCs have been applied to the repair of injured tendons and
cartilage23, the treatment of Hodgkin’s lymphoma and other cancers24, and the restoration of beta
cell function in diabetes25. BMSCs have been utilized to treat AIDS26, neurodegenerative
diseases27, and aplastic anaemia28. iPSCs have been shown to be promising in the treatment of
diabetes, COPD and liver degeneration29. A shift of viewpoint acknowledges that MSCs affect
damaged tissue repair through paracrine or cell-to-cell communication to stimulate host cells13.
MSCs were traditionally isolated from the iliac crest bone marrow, which was first reported by
Friedenstein in 197630. This method is generally adopted and widely used in regenerative
medicine. However, the procedure involving iliac crest bone marrow aspiration makes routine
isolation of MSC for craniofacial regenerative therapy difficult, especially in dental offices 31. In
addition, studies have suggested that site specific differences exist in MSCs derived from iliac
crest compared to orofacial (maxilla and mandible) origins31. For craniofacial regeneration, cells
from craniofacial tissues may be more beneficial compared to those from iliac crest32.
Currently MSCs can be obtained from several different dental tissues33. Periodontal ligament is a
fibrous and vascular tissue that contains progenitor cells that have features seen in mesenchymal
stem cells34. MSCs can be harvested from periodontal ligament tissue of surgically extracted
third molars35. Human dental pulp, apical papilla, and dental follicle are also potential sources
for MSCs33. Dental tissue derived MSCs can promote craniofacial wound healing including
2

periodontal tissue regeneration. For example, periodontal ligament progenitors were
demonstrated to enhance bony defect regeneration in animal models36, and improve clinical
parameters in humans with deep intrabony defects37. Dental pulp stem cells were seen to
improve mandibular bone defect repair after 3rd molar extraction when delivered in a collagen
sponge38.
MSCs derived from alveolar bone (aBMSCs) has emerged as another important stem cell
population for regenerative dentistry and implant therapy. Such stem cells can be achieved
through the use of bone cores and/or marrow aspiration during dental extractions or implant
therapy39. aBMSCs have a better accessibility than other dental MSCs and are considered the
primary cells responsible for extraction socket healing and implant osseointegration. Therefore,
better understanding of aBMSCs may provide valuable information regarding important aspects
of craniofacial and dental wound healing.
A recent paper by Mason et al. described the standardization and safety of aBMSC isolation40.
They isolated aBMSCs by alveolar bone marrow aspiration (~0.5cc) from 45 patients. Results
from in vitro and in vivo experiments clearly demonstrated the reliability of using small volume
aspiration to extract aBMSCs. However, they only collected samples from implant preparation
sites, which significantly limits the application of this technique to implant patients only. Tooth
extraction is a much more widely performed procedure in dentistry. It has been reported that
aBMSCs may be isolated by bone marrow aspiration from 3rd molar extraction sites31, however,
it is unknown if this would be as efficient when applied to other extraction sites. It is also not
clear whether bone marrow aspiration from extraction sites will be as effective as other technique
such as bone core harvesting.
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Although the use of MSCs in regenerative medicine is well documented in the literature,
research pertaining to the use of aBMSCs in periodontal regeneration is limited. Therefore, the
cellular characteristics of aBMSCs derived from aspiration of the bone marrow from an alveolar
post extraction sockets are largely unknown.
The aims of this study were to extract mesenchymal stem cells from alveolar bone and evaluate
their regenerative potential based on their osteogenic differentiation potential, population
doubling time, surface marker characteristics and to investigate which method was more
predictable in isolating MSCs from alveolar ridges. Once a reliable method is established, new
studies can be developed to investigate the difference in MSCs derived from patients with
different conditions such as diabetes and smoking.
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Methods
Clinical procedures and sample collection
Approval for the study was granted by Virginia Commonwealth University Institutional Review
Board (HM20013027). Patients in the Graduate Periodontics department who received routine
dental extractions or dental implant treatment were screened by their primary provider. Patients
that qualified for the study based on a checklist of inclusion and exclusion criteria (Figure 1) and
were willing to participate the study were consented by the study coordinator. The patient then
received either a dental extraction or implant placement by their primary provider using standard
operating procedures.
The following protocols were followed to collect samples during the surgical procedures:
Group 1 (dental extraction): Following extraction of the tooth, the clinician inserted a 22.5gauge needle connected to a heparinized 1cc syringe into the extraction socket, and
approximately 0.5-1 cc of marrow aspirate (blood) was obtained. The clinician then
continued with the surgery and post-surgical management based on the clinical situation.
Group 2 (dental implant): After elevation of a gingival flap at the position where the implant
was planned to be placed, a bone core of 2×5 mm was harvested with a trephine bur as the
step of initial osteotomy drilling. The bone core was stored in sterile saline before sending it
the lab for analyses. Next, a 22.5-gauge needle connected to a 1cc heparinized syringe was
inserted into the marrow space, and approximately 0.5-1 cc of marrow aspirate was obtained.
Cell culture

5

Alveolar bone marrow tissue samples were re-suspended in cold minimum essential alpha
medium (αMEM; Gibco, Carlsbad, CA, USA) and centrifuged at 600 g for 10 min at room
temperature. The supernatant was removed and the cell pellet was re-suspended in 5 mL aMEM
with 15% fetal bovine serum (FBS; Gibco). The cell suspensions were then transferred to T-25
tissue culture flasks and allowed to sit undisturbed without media change for 5 days in a 37°C
humidified tissue culture incubator at 5% CO2. Non-adherent cells were removed following 5
days in culture, and medium was changed to aMEM-10% FBS and changed every 2 to 3 days
thereafter. Once adherent cells reached 80% to 90% (approximately 10-14 days), the aBMSCs
were then collected and subcultured up to passage 3. Human BMSCs from iliac crest were
purchased from RoosterBio (Frederick, MD, USA) and cultured in expansion media until they
were ready to in vitro experiments. Human gingival fibroblasts (HGFs) were primary cells from
one donor. They were a courtesy of Dr. William Giannobile in University of Michigan and Dr.
Martha Somerman from NIDCR, and maintained in DMEM with supplements of 10% FBS and
1% Penicillin-Streptomycin. During the osteogenic experiments, same media were used for all
the cells including hBMSCs and HGFs.
Population doubling time (PDT)
In order to evaluate the aBMSC proliferation and expansion rates in vitro, population doubling
times were obtained for the samples. The average PDT was calculated between passage 1 (P1)
and passage 2 (P2). An online website (https://doubling-time.com/compute.php) was used, which
uses the following formula:
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Initial concentration = the seeding cell number
Final concentration = the cell number in the flask at the time of harvest.
The unit of duration is hour.
Flow cytometry
Flow cytometry was performed on samples to evaluate the expression of MSC markers
according to the Mesenchymal and Tissue Stem Cell Committee of the International Society for
Cell Therapy (ISCT). CD 73, CD 90, CD 105, CD 146, and CD 45 MSC markers were used.
aBMSCs were harvested from T75 flasks by 0.25% Trypsin, transferred into tubes, washed with
DPBS, and incubated with blocking solution. The cells were then incubated with specific
antibodies conjugated with a fluorochrome or isotype control antibodies for 30-45 minutes. Cells
were washed extensively at each step. For fluorochrome compensation, antibodies were added to
UltraComp eBeads (eBioscience) according to manufacturer’s protocol. Analysis was performed
on BD FACSAria™ II High-Speed Cell Sorter in VCU flow cytometry core. The list of
antibodies included:


PE conjugated anti human CD45 antibody, R&D MSC Marker kit (FMC002)



Brilliant Violet 421 conjugated anti human CD73 antibody, #344007, Biolegends,
San Diego, CA, USA



APC conjugated anti human CD90 antibody, R&D MSC Marker kit (FMC002)



PE/Cy7 conjugated anti human CD105 antibody, #323217, Biolegends, San Diego,
CA, USA
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Brilliant Violet 711 conjugated anti human CD146 antibody, #323217, Biolegends,
San Diego, CA, USA



PE/Cy7 conjugated anti mouse IgG1 k antibody, #400125, Biolegends, San Diego,
CA, USA



APC conjugated anti mouse IgG2 antibody, R&D MSC Marker kit (FMC002)



PE conjugated anti mouse IgG1 antibody, R&D MSC Marker kit (FMC002)

Osteogenic potential
The osteogenic potential of the samples was evaluated by the level of alkaline phosphatase
(ALP) activity. Briefly, cells from different donors were cultured in 24-well plates with growth
media for 24 hours, at which time the media were changed. Full media (DMEM with 10% FBS,
1% APS) was added to half of the plates. Osteogenic media (full media with the supplements of
50 µg/ml ascorbic acid, 10 mM β-glycerophosphate, 10 nMdexamethasone) was added to the
other half of the plates. Media were changed every 3-4 days. At day 0, 3, 7 and 14 days, cells
were harvested with 200 ul 0.05% Triton X-100. Total cell DNA was measured by Picogreen
assay (Promega) and protein content were quantified by Pierce BCA protein assay
(Thermoscientific). The ALP activities of cell lysates were then measured as a function of pnitrophenol hydrolysis from p-nitrophenylphosphate at pH 10.2. The results were normalized to
the total protein contents.
Statistical analysis
This was a pilot study to test the feasibility of different techniques, and therefore we were not
able to perform statistical analysis on some of the experiments such as measuring PDTs. For
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other in vitro experiment, only one donor was selected from each group. Statistical analysis was
performed based on the results of 4 technical replicates of each cell type. The results were
expressed as means ± standard error of the mean (SEM), and graphs were prepared using Graph
Pad Prism 7.02 (Graph Pad Software, CA, USA). One-way analysis of variance (ANOVA) was
conducted, followed by Tukey’s multiple-comparison test. P-value smaller than 0.05 was
considered to be significance. P-values were indicated using asterisks as follows: * (p<0.05), **
(p<0.01), *** (p<0.001), **** (p<0.0001). Statistical analysis was not performed in the cell
surface marker experiment because only one donor was selected in each cell type and there was
no technical replicate.
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Figure 1: Inclusion and Exclusion Criteria for patient selection
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Figure 2: Flowchart summarizing patient selection and treatment groups.
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Table 1: Summary of 3 different harvesting techniques
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Results
Success rates of generating aBMSCs from different tissue sources
Bone marrow aspiration samples from extraction sites were collected from 7 subjects and, of
these, 3 were able to generate aBMSCs (Table 1 and Figure 2). Additionally, in 5 subjects who
were receiving implant surgeries, bone marrow aspiration samples were collected from
osteotomy sites and obtained the bone cores. aBMSCs were able to be generated from 3 marrow
aspiration samples and from 4 bone cores. These cells had similar morphological characteristics,
which were fibroblastic-like, and spindle-shaped. All of these cells were able to be expanded to
passage 2 except for one osteotomy aspiration sample. Therefore, the success rates of generating
aBMSCs from extraction aspiration, osteotomy aspiration and bone core were 42.8% (3/7), 40%
(2/5) and 80% (4/5), respectively. Bone core samples obtained during implant surgery appeared
to be the most reliable source for generating aBMSCs.
Cell proliferation capability
Cell proliferation capability was further assessed by calculating the PDT and a DNA assay. The
average PDTs for samples from extraction aspiration, osteotomy aspiration and bone core were
43.62 h, 54.72 h and 49.46 h, respectively (Table 1). Although no statistical analysis was
performed due to the small sample size (only 2 samples from osteotomy aspiration), it appeared
that the proliferation rate of aBMSCs derived from osteotomy aspiration was slower than other
cells. We selected one subject from each sample type and measured the changes in DNA content
after expansion. Similarly, we found that cells from extraction aspiration had the fastest
proliferation rate among the three sample types, followed by bone core and osteotomy aspiration
(Figure 3 and Figure 4). Similar results were seen both in growth medium (NT) and osteogenic
13

medium (OM). In this experiment, we also used BMSCs from long bone and gingival fibroblasts
(HGFs) as controls. Interestingly, aBMSCs appeared to grow faster than long bone BMSCs, but
slower than HGFs (Figure 4).
MSC characterization by surface markers
We also identified the cell surface markers by fluorescence-activated cell sorting (FACS) in each
of the three types of samples. Following isolation and cell expansion (at passage 3), aBMSCs
derived from extraction aspiration, osteotomy aspiration and bone core expressed high level of
CD 73 (96.53%-97.89%), CD90 (98.19%-99.80%), and CD105 (85.02%-91.71%) (Table 2).
Similar results were seen in the BMSCs from long bone and HGFs. However, the expression of
another MSC marker, CD146, varied significantly among different samples. Long bone BMSCs
exhibited the largest percentage (93.7%), followed by HGF (80.13%), osteotomy aspiration
(75.02%), bone core (62.15%) and extraction aspiration (23.26%). The expression of CD45, a
lymphocyte marker that was used as a negative selection marker, was very low in all of the cells
(<6.12%).
Osteogenic differentiation potential
In the previously selected cells, osteogenic medium induced the cells to differentiate to
osteoblast-like cells, which was characterized by increasing cellular ALP activities over time.
HGFs were originally used as negative controls in this experiment. To our surprise, the HGFs
that were used demonstrated a robust osteogenic potential demonstrated by the highest ALP
activity in all samples (Figure 5). When focusing on the aBMSCs, cells from bone core had the
highest ALP activity, followed by cells from extraction aspiration and osteotomy aspiration
(Figure 6). Long bone BMSCs had a higher ALP activity than aBMSCs.
14

BMSC
(iliac)
Ext
(001)
Imp-BM
(004)
Imp-BC
(004)
HGF

CD73 (%)
99.96

CD90 (%)
99.43

CD105 (%)
99.19

CD146 (%)
93.70

CD45 (%)
0

96.53

99.80

90.44

23.26

0.98

97.89

98.19

85.02

75.02

0

97.41

99.14

91.71

62.15

0.54

98.80

97.53

96.88

80.13

6.12

Table 2: Surface marker analysis using CD45, CD73, CD90, CD105 and CD146. BMSC represents human bone marrow stromal cells
from iliac. Ext represents cells derived from extraction socket aspiration. 001 represents subject 001. Imp-BM represents bone marrow
aspiration from implant osteotomy. Imp-BC represents bone core tissue from implant osteotomy. 004 represents subjects 004. HGF
represents human gingival fibroblast.
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Figure 3: DNA contents on Day 0 and Day 3 of different samples. NT: no treatment. OM: osteogenic media. HGF2X represents
human Gingival Fibroblast with 2X cell number. HGF1X represents human gingival fibroblast with 1X cell number. Ext-001: aspirate
from extraction socket from subject 001. BC-004: bone core sample from subject 004. BM-004: bone marrow aspirate from osteotomy
site from subject 004. R4: BMSCs from human iliac. DNA was measured in ng/ul. The mean of 3 or 4 replicates was presented
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Figure 4: DNA fold changes. Rate of proliferation determined by the change of DNA content between Day 3 and Day 0, either under
NT or OM treatment. NT represents the no treatment group. OM represents the osteogenic media group. HGF2X represents human
Gingival Fibroblast with 2X cell number. HGF1X represents human gingival fibroblast with 1X cell number. Ext-001: aspirate from
extraction socket from subject 001. BC-004: bone core sample from subject 004. BM-004: bone marrow aspirate from osteotomy site
from subject 004. R4: BMSCs from human iliac.
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Figure 5: ALP activities of
different samples after
normalized to total protein
content (umol/ug/min). NT: no
treatment. OM: osteogenic
media. Ext-001: aspirate from
extraction socket from subject
001. BC-004: bone core sample
from subject 004. BM-004: bone
marrow aspirate from osteotomy
site from subject 004. R4:
BMSCs from human iliac.
HGF1X represents human
gingival fibroblast with 1X cell
number, HGF2X represents
human Gingival Fibroblast with
2X cell number. The mean of 3
or 4 replicates was presented. *:
P < 0.05; **: P < 0.01; ***: P <
0.001; ****: P < 0.0001.
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Figure 6: Comparison of ALP activities of MSCs from alveolar bone and long bone (umol/ug/min). Figure 4 was reformatted after the
removal of HGFs. NT: no treatment. OM: osteogenic media. Ext-001: aspirate from extraction socket from subject 001. BC-004: bone
core sample from subject 004. BM-004: bone marrow aspirate from osteotomy site from subject 004. R4: BMSCs from human iliac.
The mean of 3 or 4 replicates was presented. ****: P < 0.0001.
19

Discussion
Historically MSCs haven been isolated from bone marrow of iliac crest 15. Iliac crest harvest has
been considered as the gold standard for obtaining MSCs, however, research has shown that the
use of MSCs derived from different dental tissues may facilitate regeneration in animal models36.
In this study different techniques were utilized to obtain MSCs through the use of bone core and
marrow aspirate obtained during implant surgery as well as bone marrow aspirate obtained from
extraction sockets. The results demonstrated different success rate of generating aBMSCs from
different tissue sources, ranging from 40% to 80% with bone core samples being the most
predictable sources in generating aBMSCs.
Matsubara et al.31 also described the different success rates of generating aBMSCs from different
techniques. They showed that extraction of wisdom teeth followed by marrow aspiration had
greater success rates compared to dental implant aspiration after initial osteotomy. The authors
suspected that this was related to the age of the subjects, as younger individuals were recruited
for 3rd extraction compared to individuals recruited for implant surgery. The study did not
examine bone core success rate at generating aBMSC. The results of the present study
demonstrated that extraction aspiration success rates were slightly higher when compared to
osteotomy aspiration, however, bone cores showed the highest success rates at generating
aBMSC. This may be associated with the larger tissue volumes obtained from bone cores than
those of marrow aspirates.
In a study by Mason et al39 bone marrow samples were collected from 45 patients and aBMSCs
were generated using three different techniques including; osteotomy aspiration, bone core, and
bone core combined with osteotomy aspiration. The authors observed varying success rates with
20

the combination technique yielding a success rate of 100%, followed by the bone core technique
at 97.5% and the osteotomy at 82% success rate. In comparison, success rates in the present
study were lower with 40% for the osteotomy aspiration and 80% for the bone core technique. It
is possible that the reduced success rates in the present study may be attributed to the small
sample size of 12 patients.
When comparing population doubling times (PDT), the results of this study demonstrated that
aBMSCs from extraction aspirates had higher proliferation rates compared to those of osteotomy
aspirates and bone cores (43.62h vs 54.72h vs 49.46h). When comparing the osteotomy aspirate
versus bone core techniques, Mason et al.39 showed that proliferation was at least twice as fast
for bone cores compared to osteotomy aspirates alone. These findings were supported by the
present study in that bone core samples showed higher proliferation rates compared to the
osteotomy aspirates however the rate was not twice as fast.
MSC characterization was accomplished by studying different cell surface markers by using
fluorescence-activating cell sorting in the three types of samples. All of the aBMSCs from
extraction aspiration, osteotomy aspiration and bone core expressed high levels of CD 73
(>96%), CD90 (> 98%), and CD105 (>85%). These results were also seen in long bone and
HGFs. Mason et al.39 evaluated aBMSCs characteristics and found high levels of CD73, CD 90
and CD105 in their samples. Matsubara et al.31 examined the difference between cell surface
antigens of alveolar and iliac bone marrow stromal cells and showed that none of the cell surface
antigens differed between the two groups. This was also the case in the current study with the
exception that a large variance was observed in regard to CD146, in which iliac BMSCs showed
higher expression than aBMSCs.
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When comparing osteogenic potential Matsubara et al.31 showed that iliac BMSCs had similar
ALP activity when compared to aBMSCs. The results of the current study suggest that ALP
activity in iliac BMSCs was higher than that in cells from bone core, osteotomy aspiration, and
extraction aspiration. Although this study used a small sample size, the results indicated that
MSCs derived from jaw bones and long bones may have different properties. Originally, HGFs
served as a negative control in the study. In unexpected results, the HGFs tested in this study
demonstrated a robust proliferation potential and a much stronger ALP activity than each of the
other cells. This difference may be attributable to the genetic background of this specific donor.
Another possible explanation is that MSCs can also be found in gingival tissues41. In the future,
it may be interesting to study the regenerative potential of HGFs.
Several limitations were noted within this study. The sample size consisted of only 12 subjects,
which is not an adequate size to achieve any statistical relevance. Although the study obtained
samples in a standardized method, errors may possibly have occurred during collection,
transportation, and/or analysis of the samples. Due to the small sample size it was not possible to
evaluate the effects of sex, age, and health status on generating aBMSCs from different tissue
sources. In addition, there was no attempt to account for differences in bone density among
samples, grafted versus non grafted sites, maxilla versus mandible, and bone core volume.
Another limitation was that in vivo bone formation of the MSCs obtained from the patients was
not tested. It is also important to note that MSC can be obtained from PDL cells from during
extraction of 3rd molars35,42,43 and from the dental pulp33. Finally, this study did not compare the
differences between aBMSCs with MSCs from other dental tissues.
Overall, this study compared three different techniques to obtain aMBSCs: extraction socket
aspiration, osteotomy aspiration and bone core digestion. Further research is required to evaluate
22

the potential use of aBMSCs in periodontal regeneration and other regenerative procedures in
dentistry.
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Conclusion
This study compared three different methods to obtain aBMSCs, including: extraction socket
aspiration, osteotomy aspiration and bone core digestion. Bone core samples obtained during
implant surgery may be a more reliable source for generating aBMSCs than extraction socket
aspiration and osteotomy aspiration. MSCs derived from different methods may have different
characteristics in regard to proliferation, differentiation potential and cell surface markers.
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